Drug intelligence / Profile preview

pravastatin + cyclosporine

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

This combination involves **pravastatin**, a statin used to lower cholesterol and prevent cardiovascular disease, and **cyclosporine**, an immunosuppressant used primarily in organ transplantation to prevent rejection. The coadministration of these drugs can increase pravastatin levels due to cyclosporine's inhibition of transporters like OATP1B1 and P-glycoprotein, potentially leading to higher exposure of pravastatin[2][3].

Targets

OATP1B1 (Organic anion transporting polypeptide 1B1)MRP2 (Canalicular multispecific organic anion transporter 1)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)SLCO1B3 (Organic anion transporting polypeptide 1B3)ABCB1 (P-glycoprotein)CN (Calcineurin)

Beyond the preview

Go deeper on pravastatin + cyclosporine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pravastatin + cyclosporine.

Explore the full profile